Breaking News
September 21, 2018 - Study reveals promising new drug candidate to treat acute renal failure
September 21, 2018 - Neural signal that urges to eat overpowers the one that says to stop
September 21, 2018 - Scientists achieve breakthrough in accelerated diagnosis of multi-resistant hospital pathogens
September 21, 2018 - Researchers simulate how different breast tissues respond to heat from MRIs
September 21, 2018 - Despite red flags at surgery centers, overseers award gold seals
September 21, 2018 - Zapping Airway Nerves May Help COPD Patients Breathe
September 21, 2018 - Researchers find answers as to why some people are at risk of gout
September 21, 2018 - Stars of Stanford Medicine: Genetic counseling and compassion
September 21, 2018 - Health insurance ads have shifted over time due to health plans offered via ACA
September 21, 2018 - Use of transcranial electrical stimulation to bolster creativity has far-reaching implications
September 21, 2018 - Scientists find way to boost efficacy of powerful antimalarial drug with anti-cancer medicines
September 21, 2018 - Weighing the risks and benefits of drug tapering—two patients, two perspectives
September 21, 2018 - The “exposome” revealed: a barrage of bacteria, chemicals, microscopic animals and more
September 21, 2018 - Top three immune boosting recommendations to ward off freshers’ flu
September 21, 2018 - Young children’s oral microbiota could serve as early indicator for obesity
September 21, 2018 - Older individuals with multiple sclerosis report higher quality of life than younger counterparts
September 21, 2018 - LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines
September 21, 2018 - AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
September 21, 2018 - Alzheimer’s drug may stop disease if used before symptoms develop
September 21, 2018 - Human skeletal stem cell can generate cartilage, bone
September 21, 2018 - UK and European research collaborations receive vote of confidence by three major cancer charities
September 21, 2018 - Microbiota in the intestines and cell stress cause colon cancer
September 20, 2018 - Arizona EMTs have 39% higher risk for suicide than general public
September 20, 2018 - Driving and older adults: MedlinePlus Medical Encyclopedia
September 20, 2018 - Brain region for stress control is enlarged in people with depression, finds study
September 20, 2018 - Researchers test autobiographical memory for early Alzheimer’s detection
September 20, 2018 - Organizations join forces to help teens with severe mental health challenges | News Center
September 20, 2018 - Neurons in the human brain can encode numerical information
September 20, 2018 - Potential drugs to treat neurodegenerative diseases garner $3 million grant
September 20, 2018 - Processing speed important to higher order cognitive function in multiple sclerosis patients
September 20, 2018 - Helping a patient survive a hurricane
September 20, 2018 - Tafamidis Treats Transthyretin Amyloid Cardiomyopathy
September 20, 2018 - Low academic achievement can lead to drug abuse decades later, research finds
September 20, 2018 - Study identifies stem cell that gives rise to new bone, cartilage in humans | News Center
September 20, 2018 - Celltrion and Emory University sign ‘Incubation’ agreement to develop new drug candidates for atherosclerosis
September 20, 2018 - TGen and PNOC take part in launch of NIH-supported Kids First Data Resource Portal
September 20, 2018 - Could Household Cleaners Make Your Kid Fat?
September 20, 2018 - Addiction nonprofit makes searching for services simple
September 20, 2018 - We are bombarded by thousands of diverse species and chemicals | News Center
September 20, 2018 - Experts to Present Prostate Cancer Advances at Patient Summit
September 20, 2018 - Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia
September 20, 2018 - Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA
September 20, 2018 - Study could allow doctors to screen patients at risk from Aspergillus
September 20, 2018 - Emergex signs MoU with Brazil’s Fiocruz for development of viral vaccines
September 20, 2018 - The ‘real you’ is a myth – we constantly create false memories to achieve the identity we want
September 20, 2018 - Researchers describe cell mechanism that optimizes proteins production in stressful situations
September 20, 2018 - Cell Medica successfully doses first patient with CMD-501 targeting pediatric neuroblastoma
September 20, 2018 - Sesen Bio to present its three-month Phase 3 VISTA Trial data at Global Congress
September 20, 2018 - Senators unveil legislation to protect patients against surprise medical bills
September 20, 2018 - Study provides insights into development of special-purpose cosmetic products
September 20, 2018 - Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1
September 20, 2018 - 91% of people around the world believe medical research will result in dementia cure
September 20, 2018 - DePuy Synthes introduces CONCORDE LIFT Expandable Interbody Device at EUROSPINE 2018
September 20, 2018 - Manx Telecom unveils MT clearSound that improves clarity of mobile phone calls
September 20, 2018 - Mediterranean-style diet appears to reduce stroke risk in women
September 20, 2018 - AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
September 20, 2018 - Characterization of pregnancy microbiome reveals variations in bacterial diversity
September 20, 2018 - New guidance for treatment of bone loss in hematologic stem cell transplant Recipients
September 20, 2018 - Experts to present research on prevention, management of dysphagia at international conference
September 20, 2018 - New study focuses on two-way gene switches controlling gene activity
September 20, 2018 - Zika virus could become a weapon against brain cancer
September 20, 2018 - Home-based video game exercises can reduce chronic low back pain in older people, study finds
September 20, 2018 - Investigators find that bile acids reduce cocaine reward
September 20, 2018 - Cannabinoid drugs reduce perceived unpleasantness of painful stimuli and increase tolerance
September 20, 2018 - Health care companies’ data could enable more accurate flu season forecasts
September 20, 2018 - Geroscience takes center stage in Journal of the American Medical Association
September 20, 2018 - Ambient Particulate Matter Linked to Emergency Asthma Care
September 20, 2018 - Patient satisfaction with plastic surgery—it’s the surgeon, not the practice
September 20, 2018 - Medicine is a team sport – and that’s exactly how it should be
September 20, 2018 - Logos Biosystems releases new electrophoretic tissue clearing system with twice the features in half the space
September 20, 2018 - Novel micro-platform reveals never-before-seen behaviors of cancer cells
September 20, 2018 - PAREXEL partners with Datavant to enhance clinical study design and generate real-world evidence
September 20, 2018 - Robert Koch Institute publishes new data on allergies, mental health problems, and accident injuries
September 20, 2018 - Study finds higher readmission rates in for-profit hospitals
September 20, 2018 - Encouraging youth to do strength-based exercises could help tackle child obesity
September 20, 2018 - Sleep apnea, congenital heart disease in hospitalized infants strongly associated with death
September 20, 2018 - Researchers find way to map mysterious content of non-coding RNA
September 20, 2018 - Air Pollutants Reach Placenta, Might Harm Fetus: Study
September 20, 2018 - Sleep apnea, congenital heart disease may be deadly mix for hospitalized infants
September 20, 2018 - My relative has cancer, should I worry? Encouraging cascade genetic testing
Combo Bests Targeted Agent in mRCC

Combo Bests Targeted Agent in mRCC

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and will be presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN FRANCISCO — Patients with newly diagnosed metastatic renal cell carcinoma (mRCC) lived about 3 months longer without disease progression with immunotherapy-based treatment rather than a targeted agent, a randomized trial showed.

In the subgroup of patients with PD-L1 positive tumors, initial treatment with atezolizumab (Tecentriq) and bevacizumab (Avastin) led to a median progression-free survival (PFS) of 11.2 months compared with 7.7 months for patients who received standard first-line treatment with sunitinib (Sutent). The intention-to-treat population had a median PFS of 11.2 months with the combination and 8.4 months with sunitinib, according to Robert Motzer, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

Median overall survival (OS) in the ITT population had yet to be reached, but trended in favor of the atezolizumab-bevacizumab arm. Additionally, more patients had objective responses with the combination, Motzer reported at a press briefing prior to the Genitourinary Cancers Symposium (GUCS).

“The response outcomes and encouraging immature overall survival results support improved efficacy for atezolizumab plus bevacizumab in patients with PD-L1 positive disease,” said Motzer. “Atezolizumab and bevacizumab had fewer high-grade treatment-related adverse events, low steroid use, and delayed symptom interference with daily life versus sunitinib.

“These study results support the consideration of atezolizumab and bevacizumab as a first-line treatment option for PD-L1 positive patients with advanced renal cell carcinoma.”

The results “represent an important breakthrough in cancer therapy,” said press briefing moderator Sumanta Pal, MD, of City of Hope in Duarte, California. For several years, oncologists have debated the relative merits of immunotherapy and targeted therapy as the preferred treatment for advanced RCC.

“This study, which is the first of its kind, points to a combination of both as being highly effective in delaying cancer growth, and there’s also an early trend toward improving survival,” said Pal. “The higher rate of complete response with bevacizumab and atezolizumab was also very encouraging. Achieving a complete response — total eradication of metastatic disease — is really the highest bar that we can strive for in this setting.”

Tolerability with the combination of targeted and immune therapies is another important piece of information from the study, he added. The side effect profile appeared to be superior, in some respects, to that of oral targeted agents used in the setting of mRCC.

“I would agree with Dr. Motzer that the data support consideration of atezolizumab and bevacizumab as a first-line option,” said Pal.

The trial involved 915 patients with previously untreated mRCC. Investigators in the international multicenter trial randomized the patients to the combination of atezolizumab and bevacizumab or to sunitinib, which has been standard of care as first-line therapy for mRCC for the past decade, Motzer noted. About 40% of the patients tested positive for PD-L1 expression, defined as >1% expression on tumor-infiltrating immune cells.

The trial had co-primary endpoints of investigator-assessed PFS in the PD-L1 positive subgroup and OS in the ITT population. Secondary endpoints included PFS in the ITT population, objective response rate, and duration of response.

Motzer reported findings from an analysis performed after a median follow-up of 15 months. The 3.5-month difference in PFS in the PD-L1 positive group was associated with a hazard ratio of 0.74 in favor of the atezolizumab-bevacizumab combination (95% CI 0.57-0.96, P=0.0217). Immature survival data showed a 19% reduction in the HR in favor of the combination, although the median had yet to be reached in either arm (95% CI 0.63-1.03, P=0.09).

Other endpoints consistently favored the combination treatment:

  • PFS (ITT): 11.2 versus 8.4 months (HR 0.83, 95% CI 0.70-0.97, P=0.02)
  • Survival (PD-L1+): Not reached versus 23.3 months (HR 0.68, 95% CI 0.46-1.00, P=0.05)
  • Confirmed Response (PD-L1+): 43% versus 35%
  • Confirmed Response (ITT): 37% versus 33%
  • Complete Response (PD-L1+): 9% versus 4%
  • Complete Response (ITT): 5% versus 2%

The combination of an immune checkpoint inhibitor and angiogenesis inhibitor resulted in a better safety profile. Patients randomized to sunitinib had higher rates of diarrhea, palmar/plantar erythrodysesthesia, hypertension, fatigue, dysgeusia, decreased appetite, mucositis, stomatitis, asthenia, and vomiting. The combination was associated with more proteinuria. Motzer reported that 16% of patients in the combination arm required systemic steroids to manage adverse events.

The safety and efficacy of atezolizumab and bevacizumab compared favorably with the dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), which also has been evaluated in advanced RCC, Pal noted.

“That [dual immunotherapy] regimen also demonstrated improved outcomes relative to sunitinib in patients with newly diagnosed metastatic kidney cancer, but nearly 60% of patients required steroids for management of side effects as compared with 16% in the study reported by Dr. Motzer.”

The study was supported by Roche/Genentech.

Motzer disclosed relevant relationships with Pfizer, Novartis, Eisai, Exelisix, Merck, GlaxoSmithKline, Bristol-Myers Squibb, and Roche Genentech.

2018-02-06T16:45:00-0500

Tagged with:

About author

Related Articles